SCHEMBL3769769

SCHEMBL3769769

O=C(Cc1ccccc1C(F)(F)F)N1CCN(CC(=O)N2CCN(C3CCC3)CC2)CC1

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.60
ALDH1A1 P00352 4/20 0.60
RBP4 P02753 2/20 0.52
CYP1A2 P05177 1/20 0.48
CYP2D6 P10635 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
CNR1 P21554 1/20 0.48
TACR1 P25103 1/20 0.46
PARP1 P09874 1/20 0.46
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
EPHX2 P34913 1/20 0.44
SIGMAR1 Q99720 1/20 0.43
HRH3 Q9Y5N1 2/20 0.43
POLB P06746 1/20 0.43
TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3780460 0.91 KDM4E (0.52) KDM4EALDH1A1RBP4CYP1A2CYP2D6
SCHEMBL3770228 0.85 KDM4E (0.55) KDM4EALDH1A1CNR1PARP1
SCHEMBL3769953 0.85 CYP2C9 (0.52) KDM4EALDH1A1CYP1A2CYP2D6SMN1; SMN2
SCHEMBL3767508 0.84 KDM4E (0.49) KDM4EALDH1A1SMN1; SMN2PARP1MEN1
SCHEMBL3767530 0.83 ALDH1A1 (0.55) KDM4EALDH1A1PARP1TSHR
SCHEMBL3763152 0.83 KDM4E (0.55) KDM4EALDH1A1PARP1MEN1KMT2A
SCHEMBL3772003 0.83 CCR3 (0.55) KDM4EALDH1A1PARP1MEN1KMT2A
SCHEMBL3766253 0.81 KMT2A (0.55) KDM4EALDH1A1PARP1MEN1KMT2A
SCHEMBL3773640 0.81 GPR183 (0.48) KDM4EALDH1A1CYP1A2CYP2D6SMN1; SMN2
SCHEMBL3773643 0.81 GPR183 (0.48) KDM4EALDH1A1CYP1A2CYP2D6SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 KDM4E 534/4885ALDH1A1 1210/4885RBP4 2273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.